Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Takeda Pharmaceutical: Zasocitinib, Oveprexton Positive Results Shows Takeda’s Pipeline Strength

Takeda Pharmaceutical (4502 JP): Decent 9MFY26 Show; Guidance Revision Amid New Leg of Growth

Takeda Pharmaceutical (4502 JP): Guidance Reaffirmed; Positive Data Read Outs Pave Way for Filings

Takeda Pharmaceutical (4502 JP): Guidance Revised Downwards; Vyvance Continue To Be a Pain Point

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takeda-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:11747:1" rel="noopener">Takeda Pharmaceutical (4502 JP)</a> reported FY26 revenue of ¥4505.6B, down 2%, primarily attributable to lower sales of Vyvanse, due to continued impact of generic erosion because of loss of exclusivity.</li>
<li>Takeda announced FY27 guidance expecting revenue to be ¥4640B (up 3% YoY) driven by new launches and core in-line brands. Operating profit and net profit both are expected to rise.</li>
<li>Sustained and stable performance of its Growth and Launch product portfolio, ripe late-stage pipeline augur well for long term growth prospects.</li>
</ul>



Takeda Pharmaceutical (4502 JP) reported FY26 revenue of ¥4505.6B, down 2%, primarily attributable to lower sales of Vyvanse, due to continued impact of generic erosion because of loss of exclusivity.
Takeda announced FY27 guidance expecting revenue to be ¥4640B (up 3% YoY) driven by new launches and core in-line brands. Operating profit and net profit both are expected to rise.
Sustained and stable performance of its Growth and Launch product portfolio, ripe late-stage pipeline augur well for long term growth prospects.


Takeda Pharmaceutical: Looking Forward To Pending Approvals and Late Stage Pipeline in FY27